UK-356618
CAS 230961-08-7 MFCD19443865
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} Approved Therapeutics/Drug Candidates, Bioactive Small Molecule Alphabetical Index, Cytoskeleton and Extracellular Matrix, Extracellular Matrix, Metalloproteinase Inhibitors, Pfizer Compounds, U, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
- {SNA} Approved Therapeutics/Drug Candidates, Cell Biology, Cell Signaling and Neuroscience, Cytoskeleton and Extracellular Matrix, Extracellular Matrix, Metalloproteinase Inhibitors, Pfizer Compounds
相关文献及参考
- [2]. Yan HQ, et al. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells. Oncotarget. 2016 Sep 20;7(38):62070-62083.
- [3]. Hafez S, et al. Matrix Metalloprotease 3 Exacerbates Hemorrhagic Transformation and Worsens Functional Outcomes in Hyperglycemic Stroke. Stroke. 2016 Mar;47(3):843-51.
- [1]. Fray MJ, et al. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorg Med Chem Lett. 2001 Feb 26;11(4):571-4.
- [1]. Fray MJ, et al. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorg Med Chem Lett. 2001 Feb 26;11(4):571-4.
- [2]. Yan HQ, et al. Ataxia-telangiectasia mutated activation mediates tumor necrosis factor-alpha induced MMP-13 up-regulation and metastasis in lung cancer cells. Oncotarget. 2016 Sep 20;7(38):62070-62083.
- [3].
安全信息
GHS Symbol

- H302 Harmful if swallowed 吞食有害
- R22 Harmful if swallowed 吞咽有害